Treeline Biosciences CSO Jeffrey Engelman (L) and CEO Josh Bilenker
Josh Bilenker, Jeff Engelman quiet on everything behind their $735M 'outer edge' startup
An $8 billion exit from Eli Lilly and a short-lived stint heading up oncology work at the Big Pharma post-Loxo sale have persuaded Josh …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
